Literature DB >> 21175570

Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey.

H Kawahara1, G M Drew, M J Christie, C W Vaughan.   

Abstract

BACKGROUND AND
PURPOSE: While arachidonyl ethanolamine (anandamide) produces pharmacological effects mediated by cannabinoid CB1 receptors, it is also an agonist at the transient receptor potential vanilloid type 1 (TRPV1) ion channel. This study examined the cellular actions of anandamide in the midbrain periaqueductal grey (PAG), a region implicated in the analgesic actions of cannabinoids, and which expresses both CB1 receptors and TRPV1. EXPERIMENTAL APPROACH: In vitro whole cell patch clamp recordings of glutamatergic excitatory postsynaptic currents (EPSCs) were made from rat and mouse PAG slices. KEY
RESULTS: Capsaicin (1 µM) increased the rate, but not the amplitude of miniature EPSCs in subpopulations of neurons throughout the rat and mouse PAG. Capsaicin had no effect on miniature EPSCs in PAG neurons from TRPV1 knock-out mice. In mouse PAG neurons, anandamide (30 µM) had no effect on the rate of miniature EPSCs alone, or in the presence of either the CB1 antagonist AM251 (3 µM) or the TRPV1 antagonist iodoresiniferatoxin (300 nM). Anandamide produced a decrease in miniature EPSC rate in the presence of the fatty acid amide hydrolase (FAAH) inhibitor URB597 (1 µM). By contrast, anandamide produced an increase in miniature EPSC rate in the presence of both URB597 and AM251, which was absent in TRPV1 knock-out mice. CONCLUSIONS AND IMPLICATIONS: These results suggest that the actions of anandamide within PAG are limited by enzymatic degradation by FAAH. FAAH blockade unmasks both presynaptic inhibition and excitation of glutamatergic synaptic transmission which are mediated via CB1 receptors and TRPV1 respectively.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21175570      PMCID: PMC3144535          DOI: 10.1111/j.1476-5381.2010.01157.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

Review 1.  The biosynthesis, fate and pharmacological properties of endocannabinoids.

Authors:  V Di Marzo; L De Petrocellis; T Bisogno
Journal:  Handb Exp Pharmacol       Date:  2005

2.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

3.  TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons.

Authors:  Jihong Xing; Jianhua Li
Journal:  J Neurophysiol       Date:  2006-10-25       Impact factor: 2.714

4.  Vanilloid-mediated heterosynaptic facilitation of inhibitory synaptic input to neurons of the rat dorsal motor nucleus of the vagus.

Authors:  Andrei V Derbenev; Michael J Monroe; Nicholas R Glatzer; Bret N Smith
Journal:  J Neurosci       Date:  2006-09-20       Impact factor: 6.167

5.  Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain.

Authors:  L Cristino; L de Petrocellis; G Pryce; D Baker; V Guglielmotti; V Di Marzo
Journal:  Neuroscience       Date:  2006-04-17       Impact factor: 3.590

6.  Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray.

Authors:  Fabrício Araújo Moreira; Daniele Cristina Aguiar; Francisco Silveira Guimarães
Journal:  Neuropharmacology       Date:  2006-12-05       Impact factor: 5.250

7.  Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray.

Authors:  Benjamin K Lau; Christopher W Vaughan
Journal:  Mol Pharmacol       Date:  2008-08-04       Impact factor: 4.436

8.  Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling.

Authors:  Geoffrey M Drew; Vanessa A Mitchell; Christopher W Vaughan
Journal:  J Neurosci       Date:  2008-01-23       Impact factor: 6.167

9.  The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats.

Authors:  Vito de Novellis; Enza Palazzo; Francesca Rossi; Luciano De Petrocellis; Stefania Petrosino; Francesca Guida; Livio Luongo; Annalucia Migliozzi; Luigia Cristino; Ida Marabese; Katarzyna Starowicz; Vincenzo Di Marzo; Sabatino Maione
Journal:  Neuropharmacology       Date:  2008-06-20       Impact factor: 5.250

Review 10.  Role of TRPV1 receptors in descending modulation of pain.

Authors:  Enza Palazzo; Francesco Rossi; Sabatino Maione
Journal:  Mol Cell Endocrinol       Date:  2008-02-02       Impact factor: 4.102

View more
  24 in total

1.  Opposing roles for cannabinoid receptor type-1 (CB₁) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats.

Authors:  Plínio C Casarotto; Ana Luisa B Terzian; Daniele C Aguiar; Hélio Zangrossi; Francisco S Guimarães; Carsten T Wotjak; Fabrício A Moreira
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Authors:  Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

3.  Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine.

Authors:  Simon Akerman; Philip R Holland; Michele P Lasalandra; Peter J Goadsby
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

4.  Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium.

Authors:  Paul J Brighton; Timothy H Marczylo; Shashi Rana; Justin C Konje; Jonathon M Willets
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 5.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

6.  The leukotriene B4 receptors BLT1 and BLT2 form an antagonistic sensitizing system in peripheral sensory neurons.

Authors:  Sebastian Zinn; Marco Sisignano; Katharina Kern; Sandra Pierre; Sorin Tunaru; Holger Jordan; Jing Suo; Elsa-Marie Treutlein; Carlo Angioni; Nerea Ferreiros; Andreas Leffler; Natasja DeBruin; Stefan Offermanns; Gerd Geisslinger; Klaus Scholich
Journal:  J Biol Chem       Date:  2017-02-27       Impact factor: 5.157

7.  Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.

Authors:  S M Todd; J C Arnold
Journal:  Br J Pharmacol       Date:  2015-11-18       Impact factor: 8.739

8.  Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey.

Authors:  Benjamin K Lau; Geoffrey M Drew; Vanessa A Mitchell; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

10.  Endocannabinoids control vesicle release mode at midbrain periaqueductal grey inhibitory synapses.

Authors:  Karin R Aubrey; Geoffrey M Drew; Hyo-Jin Jeong; Benjamin K Lau; Christopher W Vaughan
Journal:  J Physiol       Date:  2016-09-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.